Save Product
Product Details
Synonym
SERPING1, C1IN, C1-INH, C1IN, HAE1, HAE2
Source
Human Serpin G1 Protein, His Tag (SER-H52H5) is expressed from human 293 cells (HEK293). It contains AA Asn 23 - Ala 500 (Accession # P05155-1).
Predicted N-terminus: Asn 23
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 54.7 kDa. The protein migrates as 75-105 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human Serpin G1 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human Serpin G1 Protein, His Tag (Cat. No. SER-H52H5) is more than 85% and the molecular weight of this protein is around 65-85 kDa verified by SEC-MALS.
Report
Bioactivity
Measured by its ability to inhibit Recombinant Human Complement Component C1s cleavage of a colorimetric peptide substrate, N-carbobenzyloxy-Lys-ThioBenzyl ester (Z-K-SBzl). The IC50 is <4 nM (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Plasma protease C1 inhibitor
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
1 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
